Because of the increasing need to assess MAFLD and liver fibrosis that should be incorporated into the routine care of patients with T2D, the American Diabetes Association now recommends that “Patients with T2D and elevated liver enzymes (ALT) or fatty liver on US should be evaluated for the presence of NASH and liver fibrosis” [56]. This evidence concerns the gene GPT and Hepatic steatosis.